microRNA-33

Focused on three exclusive microRNA targets

LA JOLLA, Calif., Aug. 14, 2012 /PRNewswire/ — Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that it has entered into a strategic alliance with AstraZeneca to discover, develop, and commercialize microRNA therapeutics for three exclusive targets which are currently in pre-clinical development. These targets are focused on cardiovascular and metabolic diseases and oncology.

Under the terms of the agreement, AstraZeneca will make a $28M payment which includes an equity investment and an upfront payment to Regulus.

Regulus and AstraZeneca will collaborate on three microRNA targets, which include Regulus’ lead cardiovascular/metabolic disease program targeting microRNA-33 for the treatment of atherosclerosis.

Regulus will lead preclinical development and, if successful, could receive pre-clinical milestone payments.  AstraZeneca will lead and fund the clinical development and commercialization of these programs.

In addition, Regulus could also receive clinical milestones based on the successful development of microRNA therapies in each target area. Regulus is also eligible to receive significant [click to continue…]

{ 0 comments }

  • New publication in Nature shows therapeutic silencing of microRNA-33a/b for atherosclerosis:
    Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides
    K.J. Rayner et al.
    Nature 478, 404–407 (20 October 2011)
    http://www.nature.com/nature/journal/v478/n7369/full/nature10486.html

    Pre-clinical Data on miR-133
  • Regulus Therapeutics and Collaborators Publish New Pre-Clinical Data on microRNA-33 Demonstrating Key Role in Cholesterol Homeostasis and Fatty Acid Metabolism
  • Company to host webinar on October 26, 2011 to discuss findings

regulus therapeutics logoLA JOLLA, Calif., Oct. 20, 2011 /PRNewswire/ — Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, and collaborators at NYU Langone Medical Center and Wake Forest Baptist Medical Center today announced the publication of new pre-clinical research findings in the journal Nature (Rayner et al., Nature, October 20, 2011). The new data show the first demonstration of marked increases in high density lipoprotein cholesterol (HDL-C), the ‘good’ cholesterol, and suppression of plasma triglyceride levels in non-human primates through inhibition of both microRNA-33a and microRNA-33b (miR-33a/b) with proprietary chemically modified anti-miR oligonucleotides. A webinar to discuss the new data will be hosted by Regulus and features Kathryn Moore, Ph.D., associate professor in the Department of Medicine at NYU Langone Medical Center and Regulus scientists (11:00am EDT, October 26, 2011).

“In addition to atherosclerotic plaque regression and enhanced reverse cholesterol transport that we previously observed in rodents with our collaborators at NYU Langone Medical Center, anti-miR-33 treatment is now shown to [click to continue…]

Incoming search terms for this article:

{ 0 comments }